Search company, investor...
LakePharma company logo

LakePharma

lakepharma.com

Stage

Acquired | Acquired

Total Raised

$30M

About LakePharma

LakePharma is a contract research organization (CRO) specializing in antibody engineering, antibody discovery, molecular engineering, protein chemistry, bioexpression, biofunction, bioprocessing, and bioanalytics. LakePharma focuses on integrated platforms to support projects throughout the drug discovery process. LakePharma offers dedicated client services and sophisticated software to provide real-time access to project data via a secure cloud-based portal, Datasystems.On July 14th, 2021, LakePharma was acquired by Curia. Terms of the transaction were not disclosed.

Headquarters Location

520 Harbor Blvd.

Belmont, California, 94002,

United States

650-288-4891

Missing: LakePharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: LakePharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing LakePharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

LakePharma is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

838 items

LakePharma Patents

LakePharma has filed 1 patent.

The 3 most popular patent topics include:

  • Immune system
  • Immunology
  • Monoclonal antibodies
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/31/2020

7/12/2022

Clusters of differentiation, Immunology, Immune system, Monoclonal antibodies, Transcription factors

Grant

Application Date

3/31/2020

Grant Date

7/12/2022

Title

Related Topics

Clusters of differentiation, Immunology, Immune system, Monoclonal antibodies, Transcription factors

Status

Grant

Latest LakePharma News

Cell Line Development Market Size Worth $11.21Bn, Globally, by 2027 Growing at 13.3% CAGR | Exclusive Report by The Insight Partners

Aug 3, 2022

Cell Line Development Market: Competitive Landscape and Key Developments Merck KGaA, Thermo Fisher Scientific Inc., Selexis SA (JSR Corporation), BioFactura, Inc., Corning Incorporated, Sartorius AG, Lonza, GENERAL ELECTRIC, LakePharma, Inc., and WuXiAppTec Group are among the leading companies operating in the global cell line development market. In April, 2019 - Lonza introduced CellBio Services, a comprehensive portfolio of unique, custom solutions designed to meet specific, individual research application needs. In June, 2019 - Thermo Fisher Scientific introduced Cytomat 2 C-LiN Series automated incubator for cell cultures. This instrument has features such as automated Controlled humidity, in built contamination reduction system, other advance features. FloDesign Sonics is a developer of a unique acoustic cell processing platform that is applicable for the industrialization of cell and gene therapy manufacturing. Inquiry Before Purchase: https://www.theinsightpartners.com/inquiry/TIPHE100001196/ Increasing Adoption of Regenerative Medicines Drives Cell Line Development Market Growth Regenerative medicines have the potential to replace or heal tissues as well as organs damaged due to various factors, such as age, disease, or trauma; they also help normalize congenital defects. Over the last quarter of a century there has been an emergence of a tissue engineering industry, which has now evolved into the broader area of regenerative medicines. Regenerative medicines are a rapidly growing interdisciplinary field with the involvement of engineering sciences to develop clinical therapies for maintenance, repair, replacement, and enhancement of biological functions. The cell line development is a crucial and invariable part of this field as it helps understand how to treat a wide range of medical conditions, from broken bones to neurodegenerative diseases. Further, the regenerative medicines use cell-based models that have the potential to help the researchers in early-intervention treatment for degenerative diseases and traumatic injuries. Thus, the rise in adoption of regenerative medicines is fostering the demand for cell line development in the coming years. Moreover, consistent research in drug discovery is expected to foster the market growth during the forecast period. However, the risk of cell line contamination hinders the growth of the cell line development market. Additionally, the APAC countries are facing challenges due to the rising prevalence of COVID-19. As per the data of Worldometer, the total number of COVID-19 cases in the region was 7,413,721 on September 2, 2020. In addition to the adverse effects of pandemic, uncertainty around economic recovery has affected the pharmaceutical industry in the region. Major pharmaceutical companies in the region are engaged in the development of the potential COVID-19 vaccine, and research projects on other therapeutics have been put on hold; this is expected to hinder the growth of the cell line development market in APAC. Have a question? Speak to Research Analyst: https://www.theinsightpartners.com/speak-to-analyst/TIPHE100001196 Stable cell lines are widely used in a wide range application, including biologics production, drug screening, and gene functional studies. The COVID-19 pandemic led to disruptions in all phases of drug development, and it has compelled many pharmaceutical companies and clinical research organizations (CROs) to put their clinical studies on hold. The new government policies, stay-at-home orders, social distancing norms, and widespread anxiety are among the prime challenges faced by researchers conducting the ongoing studies. The cell line is an established cell culture, wherein the cells multiply in the apt growth medium and space for growth. Different cell lines are made from different cells. Cell lines enable stepwise alterations in the structure, physiology, and genetic makeup of cells under a customized environment. The increasing investments in R&D by pharmaceutical and biotechnology companies, coupled with increasing adoption of regenerative medicines, are likely to drive the growth of the cell line development market during the forecast period. In Europe, economies are severely affected by the exponential growth of COVID-19 cases. Spain, Italy, Germany, France, and the UK are among the most affected European countries. Pharmaceutical and MedTech companies are engaged in developing new therapeutics and vaccines for this disease. At the same time, the clinical and product development of other therapeutics has experienced disruption owing to remote work environments, reduced workforce, and supply chain discontinuations. Thus, the ongoing COVID-19 pandemic is likely to limit the growth of the cell line development market for a certain time period. Avail Lucrative DISCOUNTS on “Cell Line Development Market” Research Study: https://www.theinsightpartners.com/discount/TIPHE100001196/ Cell Line Development Market: Segmental Overview The global cell line development market is segmented by type, product, and application. Based on type, the market is segmented into primary cell lines, hybridomas, continuous cell lines, and recombinant cell lines. The recombinant cell lines segment held the largest share of the market in 2019; however, the hybridomas segment is anticipated to register the highest CAGR during the forecast period. Based on product, the cell line development market is segmented into equipment, and media and reagent. The media and reagent segment held a larger share of the market in 2019; and is anticipated to register a higher CAGR during the forecast period. Based on application, the cell line development market is segmented into drug discovery, bioproduction, and tissue engineering. The bioproduction segment held the largest share of the market in 2019; however, the market for the drug discovery segment is estimated to grow at the fastest CAGR during 2020–2027. Based on type, the cell line development market is segmented into primary cell lines, hybridomas, continuous cell lines, and recombinant cell lines. The recombinant cell line segment held the largest share of the market in 2019. However, the hybridomas segment is anticipated to register the highest CAGR during the forecast period. The growth of the market for recombinant cell lines is attributed to rising demand for recombinant proteins, increasing use of recombinant cell lines for biotherapeutics, and growing demand for toxicity testing. Directly Purchase Premium Copy of Cell Line Development Market Growth Report at: https://www.theinsightpartners.com/buy/TIPHE100001196/ Browse Adjoining Reports:   Cell Line Development Serum Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type (Fetal Bovine Serum, Adult Bovine Serum, Porcine Serum, Horse Serum, and Other Animal Serum); By Application (Bioproduction, Drug Discovery, Tissue Engineering and Regenerative Medicines, Toxicity Testing, and Academic Research); and Geography Biotherapeutics Cell Line Development Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Process (Transfection and Selection, Single cell cloning); Option (In-house, Outsource, Hybrid); Application (Clinical Treatment, Scientific Research, Others) and Geography Primary Cell Culture Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Primary Cells, Reagents and Supplements, Media); Application (Tissue Culture And Tissue Engineering, Vaccine Production, Gene Therapy and Regenerative Medicine, Toxicity Testing and Drug Screening, Cancer Research, Others); Separation And Culture Techniques (Explant Method, Enzymatic Disaggregation, Mechanical Separation, Others) and Geography 3D Cell Culture Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Scaffold Based, Scaffold Free, 3D Bio Printing and Magnetic Levitation, Microfluidics Based); Application (Drug Discovery, Regenerative Medicine, Cancer and Stem Cell Research); End User (Biotechnological and Pharmaceutical Institutes, Research Institutes, Others) Tissue Engineering Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Material Type (Synthetic Material, Biologically Derived Materials, and Others) and Application (Orthopedic, Musculoskeletal & Spine, Neurology, Cardiology & Vascular, Skin & Integumentary, Urology, GI & Gynecology, Cancer, and Others) Single Cell Analysis Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Consumables, Instruments); Cell Type (Human Cells, Animal Cells, Microbial Cells); Technique (Flow Cytometry, Next-Generation Sequencing, Polymerase Chain Reaction, Microscopy, Mass Spectrometry, Other Techniques); Application (Research Applications, Medical Applications); End User (Academic and Research Laboratories, Biotechnology and Pharmaceutical Companies, Hospitals and Diagnostic Laboratories, Cell Banks and IVF Centers) About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us: If you have any queries about this report or if you would like further information, please contact us: Contact Person: Sameer Joshi

LakePharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

LakePharma Rank

LakePharma Frequently Asked Questions (FAQ)

  • Where is LakePharma's headquarters?

    LakePharma's headquarters is located at 520 Harbor Blvd., Belmont.

  • What is LakePharma's latest funding round?

    LakePharma's latest funding round is Acquired.

  • How much did LakePharma raise?

    LakePharma raised a total of $30M.

  • Who are the investors of LakePharma?

    Investors of LakePharma include Curia, Summit Partners and Ampersand Capital Partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.